Aaron Yarlas1, David T Rubin2, Julian Panés3, James O Lindsay4, Séverine Vermeire5, Martha Bayliss1, Joseph C Cappelleri6, Stephen Maher1, Andrew G Bushmakin6, Lea Ann Chen7, Marco DiBonaventura8. 1. Optum, Johnston, RI, USA. 2. University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA. 3. Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain. 4. Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. 5. Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium. 6. Pfizer Inc, Groton, CT, USA. 7. New York University School of Medicine, New York, NY, USA. 8. Pfizer Inc, New York, NY, USA.
Abstract
BACKGROUND AND AIMS: This review is the first to evaluate the burden of ulcerative colitis [UC] on patients' quality of life by synthesizing data from studies comparing scores from the SF-36® Health Survey, a generic measure assessing eight quality-of-life domains, between UC patients and matched reference samples. METHODS: A systematic review of the published literature identified articles reporting SF-36 domains or physical and mental component summary scores [PCS, MCS] from UC and reference samples. Burden of disease for each SF-36 domain was then summarized across studies by comparing weighted mean differences in scores between patient and reference samples with minimally important difference thresholds. RESULTS: Thirty articles met pre-specified inclusion criteria. SF-36 scores were extracted from five samples of patients with active disease, 11 samples with a mixture of disease activity, five samples of patients in clinical remission, and 13 samples of patients following proctocolectomy with ileostomy or ileal pouch-anal anastomosis, along with respective reference samples. Clinically meaningful burden was observed in samples with active or mixed disease activity [deficits: PCS = 5.6, MCS = 5.5] on all SF-36 domains except Physical Functioning. No burden was observed in samples in remission or post-surgical patients [deficits: PCS = 0.8, MCS = 0.4] except for the General Health perception domain. CONCLUSIONS: Patients with active UC experience a clinically meaningful burden of disease across most aspects of quality of life. Patients with inactive UC exhibit negligible disease burden and are comparable to the general population on most quality-of-life outcomes. Thus, treatments which effectively induce and maintain remission may restore physical and mental health status.
BACKGROUND AND AIMS: This review is the first to evaluate the burden of ulcerative colitis [UC] on patients' quality of life by synthesizing data from studies comparing scores from the SF-36® Health Survey, a generic measure assessing eight quality-of-life domains, between UC patients and matched reference samples. METHODS: A systematic review of the published literature identified articles reporting SF-36 domains or physical and mental component summary scores [PCS, MCS] from UC and reference samples. Burden of disease for each SF-36 domain was then summarized across studies by comparing weighted mean differences in scores between patient and reference samples with minimally important difference thresholds. RESULTS: Thirty articles met pre-specified inclusion criteria. SF-36 scores were extracted from five samples of patients with active disease, 11 samples with a mixture of disease activity, five samples of patients in clinical remission, and 13 samples of patients following proctocolectomy with ileostomy or ileal pouch-anal anastomosis, along with respective reference samples. Clinically meaningful burden was observed in samples with active or mixed disease activity [deficits: PCS = 5.6, MCS = 5.5] on all SF-36 domains except Physical Functioning. No burden was observed in samples in remission or post-surgical patients [deficits: PCS = 0.8, MCS = 0.4] except for the General Health perception domain. CONCLUSIONS: Patients with active UC experience a clinically meaningful burden of disease across most aspects of quality of life. Patients with inactive UC exhibit negligible disease burden and are comparable to the general population on most quality-of-life outcomes. Thus, treatments which effectively induce and maintain remission may restore physical and mental health status.
Authors: Hamed Khalili; Åsa H Everhov; Jonas Halfvarson; Jonas F Ludvigsson; Johan Askling; Pär Myrelid; Jonas Söderling; Ola Olen; Martin Neovius Journal: Aliment Pharmacol Ther Date: 2020-07-03 Impact factor: 9.524
Authors: Christoph Lohan; Alex Diamantopoulos; Corinne LeReun; Emily Wright; Natalie Bohm; Laura Marie Sawyer Journal: BMJ Open Gastroenterol Date: 2019-07-30
Authors: Luciane de Fátima Caldeira; Helena H Borba; Fernanda S Tonin; Astrid Wiens; Fernando Fernandez-Llimos; Roberto Pontarolo Journal: PLoS One Date: 2020-09-18 Impact factor: 3.240
Authors: Edward Mezones-Holguin; Rocio Violeta Gamboa-Cardenas; Gadwyn Sanchez-Felix; José Chávez-Corrales; Luis Miguel Helguero-Santin; Luis Max Laban Seminario; Paula Alejandra Burela-Prado; Maribel Marilu Castro-Reyes; Fabian Fiestas Journal: Front Pharmacol Date: 2019-11-15 Impact factor: 5.810
Authors: Alessandro Armuzzi; Miriam Tarallo; James Lucas; Daniel Bluff; Benjamin Hoskin; Danielle Bargo; Joseph C Cappelleri; Leonardo Salese; Marco daCosta DiBonaventura Journal: BMC Gastroenterol Date: 2020-01-21 Impact factor: 3.067
Authors: Matthew J Brookes; John Waller; Joseph C Cappelleri; Irene Modesto; Marco D DiBonaventura; Natalie Bohm; Ruth Mokgokong; Olivia Massey; Robert Wood; Danielle Bargo Journal: BMJ Open Gastroenterol Date: 2020-09